Genetic alterations of lung cancer (WP1968)
Expression patterns of two major tumor suppressor pathways in lung cancer. These pathways are functionally linked to lung cancer and play role as a component of checkpoints and growth inhibitory pathways. Components which/who are activated in this pathway are given in red, those who are inactivated in blue. The dark blue ones are frequent and the light blue infrequent inactivated. Both, the p14ARF/p53 and the p16INK4A/RB pathway lead to cell cycle arrest.
AuthorsGustav , Kristina Hanspers , Martina Summer-Kutmon , Christine Chichester , Jonathan Mélius , Alex Pico , Egon Willighagen , Friederike Ehrhart , Lauren J. Dupuis , and Marvin Martens
Discuss this pathway
Check for ongoing discussions or start your own.
Are you planning to include this pathway in your next publication? See How to Cite and add a link here to your paper once it's online.
Pathway Ontologycancer pathway lung cancer pathway
Disease Ontologylung cancer
- Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. Zindy F, Eischen CM, Randle DH, Kamijo T, Cleveland JL, Sherr CJ, et al. Genes Dev. 1998 Aug 1;12(15):2424–33. PubMed Europe PMC Scholia
- Repression of p15INK4b expression by Myc through association with Miz-1. Staller P, Peukert K, Kiermaier A, Seoane J, Lukas J, Karsunky H, et al. Nat Cell Biol. 2001 Apr;3(4):392–9. PubMed Europe PMC Scholia
- HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation. Zhou BP, Liao Y, Xia W, Zou Y, Spohn B, Hung MC. Nat Cell Biol. 2001 Nov;3(11):973–82. PubMed Europe PMC Scholia
- Genetic alterations of multiple tumor suppressors and oncogenes in the carcinogenesis and progression of lung cancer. Osada H, Takahashi T. Oncogene. 2002 Oct 21;21(48):7421–34. PubMed Europe PMC Scholia